WO2016108572A3 - 콜레스테롤 관련 질환의 예방 및 치료용 조성물 - Google Patents

콜레스테롤 관련 질환의 예방 및 치료용 조성물 Download PDF

Info

Publication number
WO2016108572A3
WO2016108572A3 PCT/KR2015/014399 KR2015014399W WO2016108572A3 WO 2016108572 A3 WO2016108572 A3 WO 2016108572A3 KR 2015014399 W KR2015014399 W KR 2015014399W WO 2016108572 A3 WO2016108572 A3 WO 2016108572A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
preventing
related diseases
ldlr
pcsk9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/014399
Other languages
English (en)
French (fr)
Other versions
WO2016108572A2 (ko
Inventor
박상욱
이현숙
민동국
이나래
이찬주
양가을
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Publication of WO2016108572A2 publication Critical patent/WO2016108572A2/ko
Publication of WO2016108572A3 publication Critical patent/WO2016108572A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)

Abstract

본 발명은 콜레스테롤 관련 질환의 예방 및 치료용 조성물에 관한 것으로, 보다 자세하게는 PCSK9과 LDLR의 결합을 억제하는 화합물을 유효성분으로 함유하는 콜레스테롤 관련 질환의 예방 및 치료용 조성물로서, 간에서 PCSK9 및/또는 LDLR의 발현량을 직접적으로 조절하지 않아 이로 인한 부작용을 낮출 수 있으며. PCSK9과 LDLR의 결합을 효과적으로 억제하여 혈장의 총 콜레스테롤 수치는 효과적으로 낮추는 동시에 스타틴 계열의 약물과 병용투여 시 스타틴 계열 약물의 치료 효과를 더욱 상승시킬 수 있을 것으로 기대된다.
PCT/KR2015/014399 2014-12-30 2015-12-29 콜레스테롤 관련 질환의 예방 및 치료용 조성물 Ceased WO2016108572A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140193528 2014-12-30
KR10-2014-0193528 2014-12-30

Publications (2)

Publication Number Publication Date
WO2016108572A2 WO2016108572A2 (ko) 2016-07-07
WO2016108572A3 true WO2016108572A3 (ko) 2016-12-15

Family

ID=56285120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/014399 Ceased WO2016108572A2 (ko) 2014-12-30 2015-12-29 콜레스테롤 관련 질환의 예방 및 치료용 조성물

Country Status (2)

Country Link
KR (1) KR20160083806A (ko)
WO (1) WO2016108572A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032720A1 (en) 2017-08-09 2019-02-14 Sanford Burnham Prebys Medical Discovery Institute APELIN RECEPTOR AGONISTS AND METHODS OF USE
KR102019926B1 (ko) * 2017-10-13 2019-09-11 한국식품연구원 부테인 또는 이소유제놀을 포함하는 pcsk9 유전자의 발현 감소 또는 저밀도 지단백 수용체 증가용 조성물
US11141418B1 (en) * 2018-06-22 2021-10-12 The Board Of Regents, The University Of Texas System Methods and compositions for KRAS inhibitors
KR102245273B1 (ko) * 2019-03-15 2021-04-28 서울대학교병원 노르안하이드로이카리틴을 포함하는 심혈관 대사 질환의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096485A1 (en) * 2003-04-18 2005-05-05 Scanlan Thomas S. Thyronamine derivatives and analogs and methods of use thereof
US20140065649A1 (en) * 2011-04-29 2014-03-06 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs
WO2014107657A2 (en) * 2013-01-04 2014-07-10 Kohn Kenneth I Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096485A1 (en) * 2003-04-18 2005-05-05 Scanlan Thomas S. Thyronamine derivatives and analogs and methods of use thereof
US20140065649A1 (en) * 2011-04-29 2014-03-06 Sanofi Test systems and methods for identifying and characterising lipid lowering drugs
WO2014107657A2 (en) * 2013-01-04 2014-07-10 Kohn Kenneth I Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOSENKO, T. ET AL.: "Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 12, 2013, pages 8279 - 8288, XP002726014 *
MIN, D. K. ET AL.: "In Silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor", YONSEI MEDICAL JOURNAL, vol. 56, no. 5, July 2015 (2015-07-01), pages 1251 - 1257, XP055336667 *

Also Published As

Publication number Publication date
WO2016108572A2 (ko) 2016-07-07
KR20160083806A (ko) 2016-07-12

Similar Documents

Publication Publication Date Title
HK1207069A1 (en) Heterocyclic compounds and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1198443A1 (en) Heterocyclic compounds and uses thereof
CA2956871C (en) Compounds active towards bromodomains
HK1216175A1 (zh) 治療性化合物和組合物
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
HK1198869A1 (en) Combination treatments for hepatitis c
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
WO2013022846A3 (en) Flavonoid compounds
WO2013180834A3 (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
HK1216250A1 (zh) 8'-羟基-二氢麦角胺化合物及组合物
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
HK1231376A1 (zh) 局部制剂及其应用
HK1217495A1 (zh) 治疗活性的作为17β-羟基类固醇脱氢酶抑制剂的17-氮取代雌三烯噻唑衍生物
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016108572A3 (ko) 콜레스테롤 관련 질환의 예방 및 치료용 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15875666

Country of ref document: EP

Kind code of ref document: A2